MedTrace Logo

Metformin and Lactoferrin in Sepsis in Icu

NCT06181422 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-04-19

No results posted yet for this study

Summary

Sepsis is a life-threatening organ dysfunction triggered by an unregulated response of a host to infection. Sepsis is a reason for substantial mortality and morbidity among intensive care unit (ICU) patients. 1 Therefore, the aim of our study is to compare the safety and efficacy of metformin and lactoferrin in ICU patients with sepsis.

Conditions

Interventions

DRUG

Metformin

metformin 500 mg

DRUG

Lactoferrin

lactoferrin 100 mg

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Alaa Hemida · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2024-06-09
Completion
2024-06-09

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06181422 on ClinicalTrials.gov